EP1210106A2 - Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central - Google Patents

Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central

Info

Publication number
EP1210106A2
EP1210106A2 EP00955755A EP00955755A EP1210106A2 EP 1210106 A2 EP1210106 A2 EP 1210106A2 EP 00955755 A EP00955755 A EP 00955755A EP 00955755 A EP00955755 A EP 00955755A EP 1210106 A2 EP1210106 A2 EP 1210106A2
Authority
EP
European Patent Office
Prior art keywords
cells
polypeptide
growth factor
neural
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00955755A
Other languages
German (de)
English (en)
Inventor
Seth P. Finklestein
Evan Y. Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Childrens Medical Center Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1210106A2 publication Critical patent/EP1210106A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the central nervous system is particularly vulnerable to insults that result in cell death or damage in part because cells of the CNS have a limited capacity for repair.
  • disorders of the CNS often result in debilitating and largely irreversible degradation of a patient's cognitive and sensorimotor functions.
  • Conditions that result in nerve cell death and damage range from degenerative disorders, such as Alzheimer's disease, to ischemic episodes, such as stroke, to trauma.
  • stroke treatment has focused on limiting the extent of damage within the first few hours. Stroke is generally due to a blockage of an artery leading to the brain, resulting in the death of brain cells supplied by that artery.
  • Current treatments for stroke have centered on treatments to prevent arterial blockages (control of blood pressure, lipids, heart disease, etc.), and treatments to prevent brain damage once the blockage has occurred.
  • These latter treatments include "thrombolytic agents” (“clot busters” such as tPA) to break up arterial clots, and “neuroprotective agents,” designed to protect brain tissue at risk for stroke.
  • thrombolytic and neuroprotective agents must be administered within hours after the onset of stroke in order to be effective.
  • basic fibroblast growth factor is a protein that supports survival and axonal outgrowth from neurons.
  • bFGF basic fibroblast growth factor
  • animals recover more quickly and to a greater extent on tests of sensorimotor function of the impaired limbs (opposite to the side of the stroke). This recovery is not due to a decrease in magnitude of the original brain damage. Instead, data suggests that this enhancement of recovery may be due to enhancement of new neuronal sprouting and synapse formation in the intact remaining brain tissue. Such remodeling appears to occur in both the damaged and undamaged hemispheres.
  • Other mechanisms of recovery may include stimulation of endogenous neural stem cells within the brain that then differentiate into neurons, replacing to some extent neurons lost by stroke.
  • neural stem cells are pluripotential cells already present in the developing and mature mammalian brain that, given the appropriate stimulation, can differentiate into brain neurons and/or glial cells.
  • Several investigators have been successful in separating and cloning out such neural stem cell lines from both the murine and human brain (Snyder et al. (1997) Proc. Natl. Acad. Sci. USA, 94: 11663-11668; Gage et al. (1995) Proc. Natl. Acad. Sci. USA, 92: 11879- 11883; Kuhn et al. (1997) J.
  • neural stem cells may be advantageous for stroke recovery in at least two ways: (1) by the stem cells partially repopulating dead areas and re- establishing neural connections lost by stroke, and (2) by secretion of important neurotransmitters and growth factors required by the brain to rewire after stroke.
  • Efforts to promote recovery from brain injury in animals using neural stem cells have been described (Park et al. (1999) J. Neurotrauma 16: 675-687; Park et al. (1995) Soc. Neurosci. Abs. 21 : 2027; Stroemer et al. (1999) Soc. Neuroscience Abs. 25: 1310).
  • the invention comprises administering to a subject cells, preferably stem cells, and a neural stimulant in sufficient amounts to improve the subject's sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech capability.
  • kits of the invention provide kits for the treatment of CNS damage.
  • kits of the invention comprise stem cells and a neural stimulant.
  • the kits of the invention comprise a neural stimulant and a device for obtaining a stem cell-containing sample from a subject.
  • the kits comprise a polypeptide growth factor, and more preferably a polypeptide at least 30% identical but most preferably at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or 100% identical to one of the polypeptides of SEQ. ID. Nos. 1-3.
  • the invention provides pharmaceutical preparations comprising stem cells, a neural stimulant and one or more pharmaceutically acceptable reagents.
  • stem cells for use in the invention are cells capable of giving rise to brain cells, eg. neurons, oligodendroglia or astroglia.
  • stem cells are neural stem cells, hematopoietic stem cells, teratocarcinoma- derived cells or embryonic stem cells.
  • stem cells are obtained from the subject, and optionally cultured or enriched in vitro prior to administration.
  • stem cells of the invention may be induced to proliferate in vitro by transfection with a gene encoding one or more proliferation promoting factors, such as vmyc, SV40 T antigen, polyoma virus large T antigen, the neu oncogene or the ras oncogene.
  • proliferation promoting factors such as vmyc, SV40 T antigen, polyoma virus large T antigen, the neu oncogene or the ras oncogene.
  • the gene is strongly expressed in vitro, promoting proliferation, and poorly expressed after the cell has entered the central nervous system, such that the cell does not proliferate rapidly in vivo.
  • the neural stimulant is a polypeptide growth factor.
  • Preferred polypeptide growth factors comprise a polypeptide that is chosen from among the following polypeptide families: fibroblast growth factor family members, neurotrophin family members, insulin-like growth factor family, ciliary neuro trophic growth factor family members; EGF family members, TGF ⁇ family members, leukemia inhibitory factor (LIF); oncostatin M, interleukin-11; interleukin-6; members of the platelet-derived growth factor family, and NEGF family members. It is contemplated that, in certain embodiments, combinations of factors may be used.
  • Preferred polypeptides comprise a polypeptide with a sequence that is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or 100% percent identical to an amino acid sequence shown in any of SEQ ID ⁇ os. 1-3.
  • the neural stimulant is a modulator of neurotransmitter activity (eg. an agonist or antagonist).
  • the neural stimulant is an antidepressant, such as Prozac, an amphetamine, Ritalin, a tricyclic antidepressant such as Elavil, or combinations thereof.
  • the neural stimulant is a promoter of neuronal differentiation such as retinoic acid.
  • the neural stimulant is a so- called guidance molecule such as a netrin, a semaphorin, a neuropilin or an ephrin.
  • the neural stimulant may be transcranial magnetic stimulation.
  • the invention comprises conjoint administration of cells with a bioactive compound that is not a neural stimulant.
  • bioactive compounds include immunosuppressants such as immunophilins (eg. cyclosporin, FK506, and thalidomide) and antibiotics, such as tetracycline.
  • Cells and neural stimulants of the invention do not need to be administered in the same way or at the same time, but they are preferably administered such that their effects overlap. In preferred embodiments, administration is carried out at least 6, 10, 12 or 24 hours after the injury has occurred.
  • Figure 1 represents data from Example 1 in graphical form.
  • Figure 1A is a graph that depicts the results of forelimb placing tests in a rat stroke model. Rats were treated with bFGF alone, stem cells alone, bFGF and stem cells, or control vehicle only.
  • Figure IB is a graph that illustrates the results of hindlimb placing tests in a rat stroke model.
  • Figure 1C is a graph that illustrates the results of bodyswing tests in a rat stroke model.
  • Figure ID is a graph showing the results of spontaneous limb use tests in a rat stroke model.
  • Figure 2 represents in data from Example 2 graphical form.
  • Figure 2A is a graph that depicts the results of forelimb placing tests in a rat stroke model. Rats were treated with bFGF alone, stem cells alone, bFGF and stem cells, or control vehicle only.
  • Figure 2B is a graph that illustrates the results of hindlimb placing tests in a rat stroke model.
  • Figure 2C is a graph that illustrates the results of bodyswing tests in a rat stroke model.
  • Figure 2D is a graph showing the results of spontaneous limb use tests in a rat stroke model.
  • Figure 3 is a graph depicting the results of paw reaching tests in a rat stroke model.
  • Figure 4 presents amino acid sequences for variants of bFGF (SEQ. ID. Nos.1-3).
  • brain cells refers to cells comprising the brain, including neurons, astroglia, oligodendroglia, and microglia. Many specific cell types belong to each category. For example, neurons include dopaminergic, cholinergic and glutaminergic neurons, to name only a few.
  • Bioactive compounds is intended to include compounds with a desirable effect when used within the context of the invention.
  • Bioactive compounds include many neural stimulants (see below) as well as many compounds that are not considered neural stimulants but that also have desirable effects.
  • immunosuppressants such as the immunophilins (eg. FK506)
  • FK506 can exhibit the dual action of preventing rejection of the transplanted cells and providing a neuroprotective activity (Bavetta et al. (1999) Exp. Neurol. 158: 382-393).
  • Antibiotics, and particularly tetracyclines can suppress possible infections and also have beneficial effects on neural cells (Yrjanheikki et al. (1998) PNAS 95: 15769-74).
  • Cell culture refers generically to any composition of cells whether actively growing, differentiating, or static. Cell cultures can take on a variety of formats. For instance, a “suspension culture” refers to a culture in which cells are suspended in a suitable medium. A “continuous flow culture” refers to the cultivation of cells in a continuous flow of fresh medium to maintain cell growth or viability. “Continuous expansion” is a method of growing cells by continuous flow culture.
  • central nervous system refers to any component of the central nervous system including the brain and spinal cord, the cells and extracellular materials and fluids.
  • Constant administration is used herein in reference to the administration of cells and a neural stimulant or bioactive compound to subjects.
  • the term “conjoint administration” is not meant to indicate that the cells and the neural stimulant must be administered at the same time.
  • the components of the conjoint administration may be delivered at different times, at different time intervals and by different means. The administrations should, however, overlap in therapeutic effects.
  • culture medium is recognized in the art, and refers generally to any substance or preparation used for the cultivation of living cells.
  • developmental regulator is used herein to refer to molecules that modulate development in brain cells or stem cells with the capacity to become brain cells.
  • focal cerebral ischemia as used herein in reference to the central nervous system, is meant the condition that results from the blockage of a single artery that supplies blood to the brain or spinal cord, resulting in the death of cellular elements in the territory supplied by that artery.
  • Global cerebral ischemia is the diminution of blood flow to the entire brain, often caused by cardiac arrest or hypotension, for example.
  • cells that are particularly vulnerable to ischemia tend to die or become injured, resulting in patches of damage distributed around the brain. This differs from the type of damage that occurs in focal cerebral ischemia.
  • Guide molecules are a class of proteins, normally found in the extracellular matrix, that function to guide cells or cellular processes (axons) to locations required for proper functioning. Examples are the semaphorins, the netrins, the neuropilins, and the ephrins. (Perris et al. (2000) Mech. Dev. 95: 3-21; Wilkinson (2000) Int. Rev. Cytol. 196: 177-244; Nan Nactor et al. (1999) Curr. Biol. 9: R201-4).
  • Hematopoietic stem cells are stem cells that can give rise to cells of at least one of the major hematopoietic lineages in addition to producing daughter cells of equivalent potential.
  • Three major lineages of blood cells include the lymphoid lineage, eg. B- cells and T-cells, the myeloid lineage, eg. monocytes, granulocytes and megakaryocytes, and the erythroid lineage, eg. red blood cells.
  • Certain HSCs are capable of giving rise to many other cell types including brain cells.
  • “Multipotent” or “pluripotent” HSCs are HSCs that can give rise to at least three of the major hematopoietic lineages.
  • Homology and identity each refer to sequence similarity between two polypeptide sequences, with identity being a more strict comparison. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same amino acid residue, then the polypeptides can be referred to as identical at that position; when the equivalent site is occupied by the same amino acid (e.g., identical) or a similar amino acid (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous at that position. A percentage of homology or identity between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or “non- homologous" sequence shares less than 40 percent identity, though preferably less than 25 percent identity, with the polypeptide sequence of a bioactive polypeptide of the present invention.
  • ischemic episode is used to mean any circumstance that results in a deficient supply of blood to a tissue. Cerebral ischemic episodes result from a deficiency in the blood supply to the brain.
  • the spinal cord which is also a part of the central nervous system, is equally susceptible to ischemia resulting from diminished blood flow.
  • An ischemic episode may be caused by a constriction or obstruction of a blood vessel, as occurs in the case of a thrombus or embolus.
  • the ischemic episode can result from any form of compromised cardiac function, including cardiac arrest.
  • neural stimulant refers to a treatment that affects neural function or activity. Such treatments are typically polypeptide growth factors, for example neurotrophins or fibroblast growth factors. Such treatments also include guidance molecules and non-polypeptide molecules that are active in the brain, such as neurotransmitters, neurotransmitter antagonists or agonists, and developmental regulators. "Neural stimulants” may also be agents that affect the same signaling transduction pathways as those affected by the above listed agents. For example, a chemical that activates bFGF receptor signaling could be used as a neural stimulant. A “neural stimulant” can also include other chemical or electromagnetic treatments that alter the production of molecules that affect neural function or activity (eg. transcranial magnetic stimulation).
  • Neurosar stem cell is used to describe a cell derived from tissue of the central nervous system, or the developing nervous system, that can give rise to at least one of the following fundamental neural lineages: neurons, oligodendroglia and astroglia. Additionally, a neural stem cell must also be able to give rise to new NSCs with similar potential.
  • Multipotent or “pluripotent” NSCs are NSCs that are capable of giving rise to all of the above neural lineages as well as cells of equivalent developmental potential.
  • Neuronal function is used to refer generally to all the functions of the nervous system, eg. sensorimotor function and cognitive function.
  • Neuro epithelial stem cells are stem cell populations isolated from fetal neuroepithelial tissue. Such cells may be considered a subset of neural stem cells, as used herein. “Neuroeptihelial cells” tend to be multipotent.
  • Neurotransmitters are small molecules released from an axon for action within a synapse.
  • exemplary neurotransmitters include catecholamines (eg. epinephrine, norepinephrin and dopamine), serotonin, acetylcholine, glutamate and GABA.
  • a "patient” or “subject” to be treated by the subject method is a mammal, including a human.
  • bioactive polypeptide As used herein, both “protein” and “polypeptide” mean any chain of amino acid residues, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation).
  • a “bioactive polypeptide”, as used herein is a polypeptide that has activity as a neural stimulant. Examples are polypeptide growth factors and guidance molecules. “Bioactive polypeptides” also include active fragments and analogues of the bioactive polypeptides, which possess one or more the biological functions of those factors.
  • Polypeptide growth factors are generally secreted polypeptides, or active fragments thereof, that stimulate cell growth or growth of cell processes (eg. axons, dendrites etc.) in at least on cell type.
  • Active fragment indicates any portion of a polypeptide that has at least one activity of the full-length polypeptide. Many polypeptides have several different activities and it may be desirable to use an active fragment that has only one or a subset of these activities. The active fragment will produce at least 20%, preferably at least 50%, more preferably at least 70%, and most preferably at least 90% (including up to 100%) of the activity of the full-length polypeptide.
  • bFGF which can be polymorphic, with observed molecular weights of 17.8, 22.5, 23.1, and 24.2 kDa; all of these forms are biologically active and can be used in the invention.
  • recombinant protein refers to a polypeptide which is produced by recombinant DNA techniques, wherein generally, DNA encoding the polypeptide is inserted into a suitable expression construct which is in turn used to transform a host cell to produce the heterologous protein. That is, the polypeptide is expressed from a heterologous nucleic acid.
  • a “stroke” is a sudden loss of function caused by an abnormality in the blood supply to the brain. Stroke presents with different levels of severity ranging from “transient ischemic attack” or “TIA” (no permanent disability), to “partial nonprogressing stroke” (persistent but no calamitous damage), to “complete stroke” (permanent, calamitous neurological deficit). Ischemia (diminished or stopped blood flow) and infarction (cell damage and death within the zone of ischemia) are the pathologic processes in stroke that lead to neurologic deficits. "Ischemic stroke” is caused by an obstruction of blood vessels supplying the brain. The primary subcategories of ischemic stroke are thrombotic stroke, embolic stroke and lacunar infarctions.
  • Hemorrhagic stroke is caused by the rupture of blood vessels supplying the brain.
  • the primary subcategories of hemorrhagic stroke are subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH).
  • a “therapeutically effective amount” of, eg. cells or neural stimulant, with respect to the subject method refers to an amount of the therapeutic (in a preparation) which when applied as part of a desired dosage regimen causes an improvement in neuronal function according to clinically acceptable standards.
  • TMS Transcranial magnetic stimulation
  • TMS is a method for the stimulation of neurons by briefly generating magnetic fields with typical field strengths between 2 and 4T using coils close to the head (currents in TMS coils can be has high as 8000A).
  • TMS often involves pulses of stimulation with varying pulse and delay times.
  • TMS is known to upregulate monoamines in the brain.
  • the present invention is based in part on the surprising finding that the conjoint administration of cells and neural stimulants promotes greater recovery from CNS damage than either treatment alone.
  • the invention provides improved methods, compositions and kits for stimulating recovery of damaged brain tissue, whether damage is localized or global.
  • the invention pertains to recovery from ischemia, hypoxia and trauma.
  • the methods of the invention comprise the conjoint administration of stem cells and a neural stimulant, eg. a polypeptide growth factor or other molecule. The conjoint treatment gives a greater degree of recovery than has been possible with either treatment alone.
  • the subject method has wide applicability to the treatment of CNS damage.
  • the subject method is useful for, but not limited to, treatment of injury to the brain and spinal cord due to ischemias, hypoxia, traumas, neurodegenerative diseases, infectious diseases, cancers, autoimmune diseases and metabolic disorders.
  • disorders include stroke, head trauma, spinal trauma, hypotension, arrested breathing, cardiac arrest, Rey's syndrome, cerebral thrombosis, embolism, cerebral hemorrhage, brain tumors, encephalomyelitis, hydroencephalitis, operative and postoperative brain injury, Alzheimer's disease, Huntington's disease, Creutzfeld- akob disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
  • Thrombus, embolus, and systemic hypotension are the most common causes of cerebral ischemic episodes.
  • Other causes of cerebral ischemia include hypertension, hypertensive cerebral vascular disease, rupture of an aneurysm, an angioma, blood dyscrasias, cardiac failure, cardiac arrest, cardiogenic shock, septic shock, head trauma, spinal cord trauma, seizure, bleeding from a tumor, or other blood loss.
  • trauma can involve a tissue insult such as an abrasion, incision, contusion, puncture, compression, etc., such as can arise from traumatic contact of a foreign object with any locus of or appurtenant to the head, neck, or vertebral column.
  • traumatic injury can arise from constriction or compression of the CNS tissue by an inappropriate accumulation of fluid (for example, a blockade or dysfunction of normal cerebrospinal fluid or vitreous humor fluid production, turnover, or volume regulation, or a subdural or intracranial hematoma or edema).
  • traumatic constriction or compression can arise from the presence of a mass of abnormal tissue, such as a metastatic or primary tumor.
  • the damage caused by the above disorders is primarily located in a single region of the brain, eg. focal ischemia, certain traumas and Parkinson's disease. In other cases, damage can be more widespread or distributed across disparate regions of the brain, eg. hypoxia and global ischemia, and Creutzfeld- Jakob disease. Because certain cells of the invention are known to migrate freely throughout the brain, and because growth factors can be provided so as to be generally available to all brain tissues, it is anticipated that the methods and compositions of the invention will be useful in promoting recovery from both global and focal brain damage.
  • a treatment protocol of the invention involves administering a neural stimulant and stem cells to a patient that has suffered CNS damage.
  • CNS damage was caused by ischemia, hypoxia or trauma.
  • Treatment may include obtaining cells from the patient, optionally enriching for therapeutically useful cells, and administering the cells to the patient. In this way, the patient is not subjected to any foreign cells, which offers the advantage of avoiding immune responses to the cells.
  • the treatment regimen according to the invention is carried out, in terms of administration mode, timing of the administration, and dosage, so that the functional recovery of the patient from the adverse consequences of the central nervous system injury is improved; for example, the patient's motor skills (e.g., posture, balance, grasp, or gait), cognitive skills, speech, and/or sensory perceptions (including visual ability, taste, olfaction, and proprioception) may improve as result of treatment according to the invention.
  • the patient's motor skills e.g., posture, balance, grasp, or gait
  • cognitive skills e.g., speech, and/or sensory perceptions
  • visual ability, taste, olfaction, and proprioception may improve as result of treatment according to the invention.
  • the methods of the invention promote recovery from CNS damage by stimulation of neuronal sprouting and new synapse formation.
  • the present invention relates to unconventional and novel methods of treating CNS damage.
  • Neural stimulants of the invention include treatments, chemical or otherwise, that affect neural function or activity. Such treatments are typically bioactive polypeptides, but non- polypeptide molecules and physical treatments such as transcranial magnetic stimulation are also contemplated.
  • the neural stimulant is a polypeptide growth factor.
  • the polypeptide growth factor can be administered in a pharmaceutically acceptable carrier, and may also be administered mixed or unmixed with cells.
  • the polypeptide growth factor can be a member of the fibroblast growth factor (FGF) family; the neurotrophin family; the insulin-like growth factor (IGF) family; the ciliary neurotrophic growth factor (CNTF) family; the EGF family; the TGF-beta family; the PDGF family; the VEGF family; the leukemia inhibitory factor (LIF) family; an interleukin (eg. IL-11, IL-6, IL-1); or an oncostatin (eg. oncostatin M). Characteristics and exemplary members of each of these families are given below and in Table 2.
  • the polypeptide factor is a human polypeptide factor.
  • the FGF family contains at least 15 distinct factors that are highly conserved across mammalian species, although individual family members can be highly divergent from each other (generally 30-70% sequence identity).
  • FGFs are secreted proteins that share a basic tertiary structure composed of 12 beta-strands in a beta-trefoil fold. Most family members have mitogenic effects on various cell types and also bind heparin.
  • Exemplary members of the FGF family include: basic FGF (bFGF, FGF-2), acid FGF (aFGF, FGF-1), FGF-3 (int-2), FGF-4 (hst/kFGF), FGF-5, FGF-6, FGF-7 (KGF), FGF-8 (AIGF), and FGF-9 (GAF).
  • the neurotrophin family includes several related, secreted factors that exert their effects primarily on the nervous system.
  • Neurotrophins are generally produced as precursor proteins that are highly processed to give the mature forms. Mature neurotrophins carry a set of six cysteines that engage in disulfide bonding in the order 1-4 (ie. the first and fourth cysteines form a disulfide bond), 2-5 and 3-6.
  • neurotrophin family members have a surface composed of 3 antiparallel beta-strands, and dimerization occurs along this surface.
  • Exemplary members of the neurotrophin family are: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), neurotrophin 4/5 (NT4/5) and neurotrophin 6. (Lewin et al. (1996) Annu. Rev. Neuroscience 19:289-317).
  • the insulin-like growth factor family includes secreted proteins with a sequence and structure similar to that of insulin and a molecular weight typically in the range of 5-10 kDa. These factors can be found in the bloodstream, usually associated with one of six IGF binding proteins. Exemplary members of the family include IGF-1 and IGF-2. IGF-1 and -2 are known to promote recovery from various insults to the CNS. (Daughaday et al. (1989) Endocr. Rev. 10: 68-91; Rajaram et al. (1997) Endocr. Rev. 18: 801-831; Jones et al. (1995) Endocr. Rev. 16: 3- 34).
  • the epidermal growth factor family is a large family of related secreted factors. Members of the EGF family share at least 30% sequence homology and a set of six conserved cysteine residues in the C-terminal end of the protein. Most such proteins also contain an EGF- like domain, which is a particularly well-characterized domain that is also present in many non- EGF family member proteins. EGF family members are normally processed from larger precursors. Exemplary members of the EGF family include EGF, TGF-alpha, HB-EGF (heparin-binding EGF), amphiregulin, betacellulin, vaccinia growth factor and neu differentiation factor. (Aviezer et al. (1994) 91 : 12173-12177; Higashyama et al. (1992) J. Biol. Chem. 267: 6205-6212; Pelles et al. (1992) Cell 69:205-216).
  • the TGF-beta superfamily is an important class of molecules involved in cell-cell signaling and development in a wide range of organisms and cell types.
  • Members of the family are initially synthesized as larger precursor molecules with an amino-terminal signal sequence and a pro-domain of varying size (Kmgsley, D.M. (1994) Genes Dev. 8:133-146).
  • the precursor is then cleaved to release a mature carboxy-terminal segment of 110-140 amino acids.
  • the active signaling moiety is comprised of hetero- or homodimers of the carboxy-terminal segment (Massague, J. (1990) Annu. Rev. Cell Biol. 6:597-641).
  • TGF-beta binds directly to the type II receptor, which then recruits the type I receptor and modifies it by phosphorylation.
  • the type I receptor then transduces the signal to downstream components (Wrana et al, (1994) Nature 370:341-347).
  • members of the TGF-beta superfamily have a set of nine highly conserved cysteine residues that are involved in disulfide bonding both within and between monomers of the mature, dimerized signaling protein (Griffith et al. (1996) PNAS 93: 878-883; Luo et al. (1995) PNAS 92: 11761-11765; Schlunegger et al. (1993) J. Mol. Biol. 231 : 445-58; Daopin et al. (1993) Proteins 17: 176-92; Murray-Rust et al. (1993) Structure 15: 153-9; Archer et al. (1993) Biochemistry 32: 1164-71; Daopin et al.
  • the transforming growth factor beta family is a very large family of proteins including the TGF-beta subfamily, the bone morphogenesis protein (BMP) subfamily, the activin subfamily, and others.
  • Exemplary members of the TGF-beta subfamily include TGF-beta- 1, -2, - 3, -4 and -5.
  • Exemplary members of the BMP subfamily include osteogenic protein 1 (OP-1, BMP-7) and BMP-9.
  • N ⁇ GF vascular endothelial growth factor
  • V ⁇ GF proteins bind to cell surface receptors of the kinase domain receptor family (KDR) and fins-like tyrosine kinase group (Fit receptors).
  • KDR kinase domain receptor family
  • Ft receptors fins-like tyrosine kinase group
  • V ⁇ GF proteins form a homodimer with a cystine knot structure.
  • Platelet-derived growth factor (PDGF) shares only limited sequence similarity with V ⁇ GF (19%) but has substantial structural similarity.
  • PDGF and related family members are also cystine knot proteins and bind to their receptors in a similar manner.
  • Interleukins are secreted polypeptide factors that mediate signaling between immune cells. Many interleukins are known to have effects on the brain, particularly IL-l ⁇ and ⁇ , IL-6 and IL-11. (Van Wagoner et al. (1999) J. Neuroimmunol. 100:124-139; Ling et al. (1998) Exp. Neurol. 149: 411-23; Mehler et al. (1993) Nature 362: 62-5). Intriguingly, IL-6 and IL-11 both act in part through a receptor protein gpl30 that acts as a receptor for ciliary neurotrophic factor (C ⁇ TF), leukemia inhibitory factor (LIF) and oncostatin M.
  • C ⁇ TF ciliary neurotrophic factor
  • LIF leukemia inhibitory factor
  • leukemic growth factor macrophage growth factor, embryonic kidney-derived angiogenesis factor 2, prostatic growth factor, astroglial growth factor 2, endothelial growth factor, chondrosarcoma growth factor, cartilage-derived growth factor 1, eye-derived growth factor 1, heparin-binding growth factors class 11, myogenic growth, factor, human placenta purified factor, uterine-derived growth factor, embryonic carcinoma- derived growth factor, human pituitary growth factor, adipocyte growth factor, prostatic osteoblastic factor, and mammary tumor-derived growth factor.
  • any factor referred to by one of the aforementioned names is considered within the scope of the invention.
  • effort has been made to use commonly accepted names for factors, and any factor listed here is considered within the scope of the invention regardless of whether it is known to others by a different name.
  • the invention can also employ bioactive analogues of the aforementioned growth factors, which possess one or more of the biological functions of those factors.
  • An example is bFGF, which can be polymorphic, with observed molecular weights of 17.8, 22.5, 23.1, and 24.2 kDa; all of these forms are biologically active and can be used in the invention. It is possible to identify bioactive analogues of the aforementioned factors. Such analogues, when designed to retain at least one activity of a naturally occurring form of the polypeptide, are considered functional equivalents.
  • Bioactive analogues may also include molecules that are not polypeptides but nonetheless mimic activities of a polypeptide growth factor.
  • Bioactive analogues may also have advantageous properties, such as enhanced efficacy or more desirable stability properties (e.g., ex vivo shelf life and resistance to proteolytic degradation in vivo).
  • the analogue may be rendered either more stable or less stable to proteolytic degradation or other processes which result in destruction of, or otherwise inactivation of, the factor.
  • a short half-life can give rise to more transient biological effects can therefore allow tighter control of protein levels within or around a particular tissue.
  • a longer half-life can increase the potency of the factor.
  • bioactive polypeptides of the invention comprise a polypeptide with an amino acid sequence that is at least 30% identical to the bFGF sequence set forth in one of SEQ. ID. Nos. 1-3.
  • such bioactive polypeptides comprise a polypeptide with an amino acid sequence that is at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or 100% identical to one of SEQ. ID. Nos.1-3.
  • variations of a polypeptide factor can be generated by introducing changes into a nucleic acid sequence encoding the factor.
  • the altered nucleic acid can then be expressed to produce altered polypeptides, and the polypeptides can be assayed for various properties. Changes in nucleic acid sequences can be made individually to introduce particular, desired changes. Alternatively, libraries of semi-randomly generated variants may be produced and screened for activity.
  • the amino acid sequences for a population of bFGF homologs or other related proteins are aligned, preferably to promote the highest homology possible.
  • a population of variants can include, for example, bFGF homologs from one or more species, e.g. murine and chicken, or bFGF homologs from the same species but which differ due to mutation.
  • Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences.
  • the variegated library of bFGF variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library.
  • a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential bFGF sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g. for phage display) containing the set of bFGF sequences therein.
  • degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector.
  • the purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired bioactive analogs.
  • the synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) Annu. Rev. Biochem.
  • bFGF analogs can be generated, for example, alanine scanning mutagenesis and the like (Ruf et al. (1994) Biochemistry 33:1565-1572; Wang et al. (1994) J. Biol. Chem. 269:3095-3099; Balint et al. (1993) Gene 137:109-118; Grodberg et al. (1993) Eur. J. Biochem. 218:597-601; Nagashima et al. (1993) J. Biol. Chem. 268:2888-2892; Lowman et al. (1991) Biochemistry 30:10832- 10838; and Cunningham et al.
  • the above methods may be generalized to other polypeptide factors in addition to bFGF.
  • bFGF normally binds to the receptors FGFR1 and FGFR2. This binding is also stimulated by heparin binding.
  • a wide range of techniques are known in the art for screening gene products of combinatorial libraries, and for screening cDNA libraries for gene products having a certain property.
  • the most widely used techniques for screening large gene libraries typically comprise cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.
  • Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of variant sequences created by combinatorial mutagenesis techniques.
  • the gene library is expressed as a fusion protein on the surface of a viral particle.
  • foreign peptide sequences can be expressed on the surface of infectious phage.
  • These phage can be applied to affinity matrices at very high concentrations, allowing screening of a large number of phage simultaneously. If a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection in a suitable host, such as E. coli.
  • a suitable host such as E. coli.
  • the group of almost identical E. coli filamentous phages Ml 3, fd., and fl are most often used in phage display libraries, as either of the phage gill or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al.
  • the combinatorial library is designed to be extracellularly presented (e.g. as it occurs naturally) or optionally, secreted (e.g. the polypeptides of the library all include a signal sequence).
  • the library can be transfected into a eukaryotic cell that can be co-cultured with cells which express a functional receptor for the desired bioactive fragment. For example, one might use cells expressing a bFGF receptor to identify bioactive variants of bFGF. Bioactive analogs secreted by the cells expressing the combinatorial library will diffuse to neighboring receptor positive cells and induce a phenotypic change. Phenotypic changes may be detected using, for example, antibodies directed to epitopes that are either created or destroyed in response to factor treatment.
  • Each of these analogs can subsequently be screened for further biological activities.
  • receptor-binding analogs isolated from the combinatorial library can be tested for their effect on cellular proliferation relative to the wild-type form of the protein.
  • the activity of such analogs can also be assessed in animal models. For example, the ability of an analog to improve neural function in a a rat stroke model could be assessed to verify that an analog has the appropriate bioactivity.
  • a polypeptide may be chemically modified to create derivatives by forming covalent or aggregrative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like.
  • Covalent derivatives may be prepared by linking the chemical moieties to functional groups on amino acid side chains or at the N-terminus or at the C-terminus of the polypeptide.
  • a bioactive factor can be generated which includes a moiety, other than sequences naturally associated with the protein, that binds a component of the extracellular matrix and enhances localization of the analog to cell surfaces.
  • sequences derived from the fibronectin "type-Ill repeat”, such as a tetrapeptide sequence R-G-D- S (Pierschbacher et al. (1984) Nature 309:30-3; and Kornblihtt et al. (1985) EMBO 4:1755-9) can be added to a polypeptide factor to support attachment of the chimeric molecule to a cell through binding ECM components (Ruoslahti et al. (1987) Science 238:491-497; Pierschbacheret al. (1987) J. Biol. Chem. 262:17294-8.; Hynes (1987) Cell 48:549-54; and Hynes (1992) Cell 69:11-25).
  • polypeptide growth factors useful in the invention can consist of active fragments of the factors.
  • the activity of any given fragment can be readily determined in by methods such as those described above.
  • a fragment of bFGF that, when administered according to the methods of the invention described herein, is shown to improve performance in functional tests that is comparable to the performance that is produced by administration of the full-length bFGF polypeptide would be an "active fragment" of bFGF.
  • active fragments are described, e.g., in Baird and Gage (1997) Proc. Natl. Acad. Sci. U.S.A., 94 (13): 7047-52. It is well within the abilities of skilled artisans to determine whether a polypeptide growth factor, regardless of size, retains the functional activity of a full length, wild- type polypeptide growth factor.
  • the polypeptide factors useful in the invention are preferably substantially purified from their source material, be it cell culture, tissue sample, biological fluid, etc.
  • Substantially purified means that the purified material is at least 60% by weight (dry weight) the polypeptide of interest, e.g., a bFGF polypeptide.
  • the polypeptide composition is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, the polypeptide of interest. Purity can be measured by any appropriate standard method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
  • Substantially purified polypeptides can then be combined with other desired components, such as carriers or cells, to give a composition that is less than 60% composed of polypeptide, so long as the polypeptide is at sufficient concentration to be effective when administered to a patient.
  • polypeptide factors useful in the invention can be naturally occurring, synthetic, or recombinant molecules consisting of a hybrid or chimeric polypeptide with one portion, for example, being bFGF, and a second portion being a distinct polypeptide. These factors can be purified from a biological sample, chemically synthesized, or produced recombinantly by standard techniques (see. e.g., Ausubel et al., Current Protocols in Molecular Biology, New York, John Wiley and Sons, 1993; Pouwels et al., Cloning Vectors: A Laboratory Manual, 1985, Suppl. 1987).
  • neural stimulants that can be combined with cells according to the invention as well.
  • transcranial magnetic stimulation upregulates monoamines in the brain and is therefore expected to have beneficial effects in conjoint administration with cells.
  • neurotransmitter agonists or antagonists examples are neurotransmitter agonists or antagonists.
  • antidepressants such as Prozac, amphetamines, Ritalin, and tricyclic antidepressants such as Elavil.
  • differentiation factors such as retinoic acid which are capable of priming cells to differentiate into functioning neurons.
  • guidance molecules are a class of proteins, normally found in the extracellular matrix, that function to guide cells or cellular processes (axons) to locations required for proper functioning. Examples are the semaphorins, the netrins, the neuropilins, and the ephrins.
  • neural stimulants all of which have well-established effects on the brain, it is anticipated that other bioactive compounds that are not considered neural stimulants might be useful in combination with cells.
  • These alternative compounds are generally compounds with well-known effects on other parts of the body with more recently discovered effects on cells of the CNS.
  • One group of alternative compounds includes immunosuppressant molecules that are currently used to inhibit rejection of allografts.
  • a preferred class of such molecules are the immunophilins, such cyclosporin, FK506, and thalidomide. These molecules can exhibit dual action of preventing rejection of the transplanted cells and providing neuroprotective function.
  • Another group of alternative stimulants is the tetracyclines, classically known for their antibiotic effects, but also possessing desirable neuroprotective effects.
  • ⁇ may be administered to a subject. While not wishing to be limited by theory, it is postulated that administered cells may affect the brain in multiple ways. Cells may themselves become established in the brain and form functional connections with neurons. Additionally or alternatively, cells may produce factors that stimulate the endogenous nerve cells to form new processes and connections. Finally, cells might act to scavenge or otherwise remove or inactivate compounds that inhibit recovery from CNS damage. In view of these possibilities, it is understood that essentially any cell possessing one of the above qualities, and particularly stem cells but potentially even terminally differentiated cells, might have beneficial effects on brain function. Examples of terminally differentiated cell types that are known to have beneficial scavenging capabilities are activated lymphocytes and macrophages.
  • the cells of the invention are preferably stem cells that have the capability of giving rise to brain cells in vivo.
  • Particularly preferred cells are multipotential stem cells.
  • Such cells can be grown in vitro for clinical use.
  • stem cell types that can be used in the invention include neural stem cells, hematopoietic stem cells, embryonic stem cells, teratocarcinoma cell lines, and other stem cell types.
  • stem cell refers to cells with the capacity for unlimited or prolonged self-renewal that can give rise to more than one type of more differentiated descendant.
  • Preferred stem cells can undergo at least 10 cell divisions (under appropriate conditions) and still maintain stem cell characteristics.
  • Particularly prefened stem cells can undergo at least 25, 50 or 100 rounds of division without losing stem cell characteristics.
  • the terms "give rise to” and “produce” are used to mean not just the immediate daughter cells, but all the cells that can eventually trace ancestry to that cell.
  • “Give rise to” and “produce” also refer to changes in cell type that might occur without a cell division event.
  • Some differentiated cells also have the capacity to give rise to cells of greater developmental potential.
  • Such capacity may be natural under particular circumstances, or may be induced artificially upon treatment with various factors.
  • the cells may be considered a type of stem cell for the purposes of the invention.
  • Such stem cells may be referred to as "induced stem cells” or “differentiated stem cells”.
  • induced stem cells refers to stem cells that have been in any way disturbed from their natural cellular environment. This includes centrifugation, dissociation, dispersion or other processing. The stem cells contained in an unprocessed tissue sample are not considered “processed stem cells”.
  • Stem cells are usually rare cell types mixed with other, more differentiated cells. For the purposes of the invention, it is possible to use cell suspensions that comprise only a minority of stem cells. Such an approach is particularly useful with cells derived from a stem cell rich tissue, eg. bone marrow.
  • stem cells are enriched such that they are at least 50% pure, meaning that at least 50% of the cells are stem cells at the time of administration to a subject.
  • stem cells are at least 60%, 70%, 80% or 90% pure.
  • stem cells will be obtained from a tissue sample (eg. blood, bone marrow, fetal or adult brain tissue, etc.) wherein the desired stem cells constitute a small percentage of the cells present.
  • tissue sample eg. blood, bone marrow, fetal or adult brain tissue, etc.
  • the tissue sample is dissociated into a cell suspension and optionally, various methods are used to enrich for stem cells. Prefened procedures for dissociation of the tissue sample are ones that result in as little cell death as possible.
  • stem cells can be dissociated from tissue samples by mechanical means, e.g., mechanically sheared off with a pipette.
  • Fluid tissue samples such as blood
  • Fluid tissue samples can be fractionated by centrifugation and resuspension of certain fractions, if appropriate. Separation of different cell types and extracellular materials may also be achieved by centrifugation or settling in a density gradient of, for example Ficoll.
  • Stem cell populations may be enriched based on their tendency for continued cell growth as well as specific cellular markers, e.g., using affinity separation techniques or fluorescence activated cell sorting (FACS).
  • FACS fluorescence activated cell sorting
  • DMEM Dulbecco's Minimal Essential Media
  • the cultures may be maintained in any suitable culture vessel, such as a 12 or 24 well microplate, and may be maintained under typical culture conditions for cells isolated from the same animal, e.g., such as 37°C in 5% CO2.
  • the cultures may be shaken for improved aeration, the speed of shaking being, for example, 12 rpm.
  • stem cells can be enriched by detecting and sorting based on identifying characteristics of the desired cells.
  • monoclonal antibodies are particularly useful for identifying markers (surface membrane proteins, e.g., receptors) associated with particular cell lineages and/or stages of differentiation.
  • Procedures for separation of the subject progenitor cell may include magnetic separation, using antibody coated magnetic beads, affinity chromatography, and "panning" with antibody attached to a solid matrix, e.g., plate, or other convenient technique.
  • Techniques providing accurate separation include fluorescence activated cell sorting, which can have varying degrees of sophistication, e.g., a plurality of color channels, low angle and obtuse light scattering detecting channels, impedance channels, etc.
  • Antibodies may be conjugated with markers, such as magnetic beads, which allow for direct separation, biotin, which can be removed with avidin or streptavidin bound to a support, fluorochromes, which can be used with a fluorescence activated cell sorter, or the like, to allow for ease of separation of the particular cell type. Any technique may be employed which is not unduly detrimental to the viability of the cells.
  • EGF binds to the surface of desired cells.
  • a desired cell specifically expresses the EGF receptor
  • labeled EGF could be used to detect those cells in much the same way as described for the antibodies above.
  • Certain dyes also stain particular cell populations and can be used as part of a method for obtaining the desired cells.
  • Stem cells also typically have a distinctive morphology. Stem cells usually have a large nucleus with a relatively small amount of cytoplasm.
  • selection methods described above may be combined with the use of selective growth conditions to provide further enrichment.
  • natural and recombinantly engineered cells can be provided as feeder layers to the instant cultures.
  • Such cells can also produce an extracellular matrix that can be used as a substrate for selection methods.
  • a mitogen e.g., a substance that induces mitosis and cell transformation of a particular stem cell type can be used to cause the amplification of that population.
  • a mitogen e.g., a substance that induces mitosis and cell transformation of a particular stem cell type can be used to cause the amplification of that population.
  • cells that are not responsive to the particular factor tend not to divide while those that are responsive divide and become a greater proportion of the cell population.
  • Cells of the present invention can be characterized based on responsiveness to growth factors, specific gene expression, antigenic markers on the surface of such cells, dye staining and/or basic morphology. It is also valuable to determine the types of cells that a particular stem cell population can give rise to. Stem cells can be induced to differentiate into various cell types by changing the environmental conditions. For example, the subject progenitor cells can be recombined with the corresponding embryonic tissue to see if the embryonic tissue can instruct the adult cells to codevelop and codifferentiate.
  • Stem cells can be implanted into one of a number of regeneration models used in the art, e.g., neural stem cells will colonize and differentiate in the brain of a rat that has been lesioned (Gage et al. (1995) Proc. Natl. Acad. Sci. USA, 92: 11879-11883; Flax et al. (1998) Nature Biotechnology 16: 1033-1039).
  • Stem cells may be genetically labeled by transfection with a piece of foreign DNA. This labeling allows identification of stem cell descendants from among the host cells.
  • the progenitor cells can be contacted with one or more growth or differentiation factors which can induce differentiation of the cells. Differentiated cell types can be identified using the same general methods used to identify stem cells, eg. cell surface marker, dye staining etc.
  • DNA synthesis has been determined using a radioactive label ( 3 H-thymidine) or labeled nucleotide analogues (BrdU) for detection by immunofluorescence.
  • a radioactive label 3 H-thymidine
  • BrdU labeled nucleotide analogues
  • Growth factors may also be provided in the medium to selectively expand certain cell populations or to encourage the production of differentiated cell types.
  • Cells can be sorted by positive and negative selection.
  • positive or negative selection may be achieved by using one or more biotinylated antibodies, specific for factors on the surface of the target cells.
  • the biotinylated antibodies are introduced into the cell culture. After a specified incubation time any biotinylated antibodies which have not formed a complex with the target cells are rinsed away.
  • Immobilized avidin matrix is then added to the cell suspension.
  • the immobilized avidin matrix binds to the biotinylated antibody/antigen complex. This suspension can then be centrifuged to separate the avidin matrix.
  • the avidin may be coupled to magnetic beads such that the cells bound to the antibody are magnetically separated from unbound cells.
  • Mammalian blood cells provide for an extraordinarily diverse range of cell types.
  • Three major lineages of blood cells include the lymphoid lineage, eg. B-cells and T-cells, the myeloid lineage, eg. monocytes, granulocytes and megakaryocytes, and the erythroid lineage, eg. red blood cells.
  • Hematopoietic stem cells are cells that can give rise to cells of at least two of the above lineages in addition to producing daughter cells of equivalent multipotency.
  • the HSCs can give rise to three major blood cell lineages.
  • HSCs are capable of differentiating into many other cell types, including brain cells (Eglitis and Mezey (1997) Proc. Natl. Acad. Sci. USA, 94: 4080-4085).
  • HSCs can be isolated from a variety of tissue types.
  • Bone marrow cells are a good source of HSCs. Bone marrow cells may be obtained from a source of bone marrow, e.g., iliac crests, tibiae, femora, spine, or other bone cavities. Other sources of human hematopoietic stem cells include embryonic yolk sac, fetal liver, fetal and adult spleen and blood, including adult peripheral blood.
  • HSCs can be identified both by the types of cells they give rise to and by various cytological markers. HSCs often extrude certain dyes, such as Hoechst 33324 and Rhodamine 123 (Bhatia et al. (1998) Nature Med. 4:1038). Such dye staining properties can be used to identify HSCs among other cells of the circulatory system. Antibodies that react with certain cell markers can also be used to identify and purify HSCs. For example, mAb AC133 is thought to specifically bind to HSCs (Miraglia et al. (1997) Blood 90:5013). The Thy-1 molecule is a highly conserved protein present in the brain and hematopoietic system of rat, mouse and man.
  • Thy-1 molecule has been identified on rat, mouse and human HSCs and can be useful in identifying HSCs (U.S. Patent No. 5,914,108). Many HSCs are CD34+ and or CD38+ as well (U.S. Patent No. 5,840,580). A population of HSCs will often have some variation in cell surface markers and a positive identification may be made on the basis of the presence of at least two of the above cytological markers.
  • HSCs can also be distinguished from other more differentiated cell types by the absence of certain markers.
  • CD3, CD7, CD8, CD10, CD14, CD15, CD19, CD20 and CD33 are all typically absent from HSCs.
  • the absence of several of the above markers adds confidence to the identification of HSCs. Morphology may also help distinguish an HSC, as described above.
  • HSCs may be identified by an aggregation of multiple traits, such as mo ⁇ hology, the presence of certain markers, the absence of other markers, and the types of cells that the putative HSCs can give rise to. A positive identification does not typically require detection of all of the above markers.
  • HSCs to give rise to differentiated stem cells
  • cells may be cultured in a defined, enriched medium such as Iscove's Modified Dulbecco's Medium (IMDM), generally composed of salts, amino acids, vitamins, antibiotics and fetal calf serum.
  • IMDM Iscove's Modified Dulbecco's Medium
  • hydrocortisone tend to give rise to myeloid cells
  • cultures lacking cortisone tend to give rise to B lymphocytes.
  • various conventional methods can be used. For example culturing on methylcellulose culture can stimulate formation of erythroid cells. (U.S. Patent Nos. 5,840,580 and 5,914,108; Metcalf (1977) In: Recent Results in Cancer Research 61. Springer- Verlag Berlin, pp. 1-227).
  • Neural stem cells are cells derived from tissue of the adult or developing nervous system that can differentiate into at least one of the following fundamental neural lineages: neurons, oligodendroglia and astroglia. Additionally, neural stem cells can also give rise to new NSCs with similar potential. In preferred embodiments, neural stem cells are multipotential and give rise to cells of most or all of the fundamental neural lineages.
  • Each of the fundamental neural lineages can be distinguished by detecting lineage- specific proteins, as well as by mo ⁇ hology.
  • Neurons can be recognized by detecting, for example, microtubule- associated protein 2 (MAP2), tau, certain beta-tubulins (eg. TuJl, beta- tubulin type III), certain neurofilament proteins (eg. neurofilament L or M), neuron-specific enolase, or NeuN.
  • Oligodendrocytes can be recognized by detecting galactocerebrosidase (GalC), CNPase, myelin basic protein, or 04 protein.
  • Astrocytes can be recognized by the presence of glial fibrillary acid protein (GFAP).
  • GFAP glial fibrillary acid protein
  • NSCs can themselves be recognized by the presence of vimentin or nestin. Typically detection is done by standard immunostaining techniques using antibodies that recognize the desired proteins (Villa et al. (2000) Exp. Neurology 161: 67-84). Antibodies for each of the above markers are available from one or more of the following companies: Chemicon, Sigma- Aldrich, Boehringer-Mannheim, Santa Cruz Biotechnology, Dakopatts AB (Sweden). The expression of genes encoding lineage-specific proteins may also be used to distinguish cells of different lineage. Detection of gene expression can also be measured by a variety of well-known techniques including in-situ hybridization, fluorescent in-situ hybridization, quantitative rtPCR, Northern blot.
  • neural stem cells are maintained in a proliferative, undifferentiated state in the presence of one or more growth factors, for example: bFGF, EGF, TGF-alpha, LIF, or aFGF.
  • growth factors for example: bFGF, EGF, TGF-alpha, LIF, or aFGF.
  • Preferred factors are bFGF or EGF. Withdrawal of such factors allows differentiation into cells of distinct lineage.
  • the lineages formed depend on the environment. For example, certain NSCs introduced into the brain can form all of the different brain cell types depending on the particular environment each cell finds itself in.
  • the developmental pathway can be influenced by many factors. For example, CNTF can induce differentiation into astrocytes, PDGF can induce formation of neurons, and thyroid hormone (T3) can induce formation of oligodendroglial cells.
  • neural stem cells are obtained as described in U.S. Patent No. 5,958,767. This method is described here in brief as an example of a specific method for preparing NSCs. It is understood that many such methods exist and that the details of this method can be modified to give similar results.
  • a suspension of primary dissociated neural cells is prepared from the telencephalon of a 15 week gestational fetus. The suspension is plated on uncoated tissue culture dishes with Dulbecco's Modified Eagle Medium (DMEM) plus F12 medium (1 :1) supplemented with N2 medium (Gibco) to which bFGF and heparin or EGF is added.
  • DMEM Dulbecco's Modified Eagle Medium
  • F12 medium (1 :1
  • N2 medium Gibco
  • Cell aggregates are dissociated when they grow to a size larger than 10 cell diameters in size. Dissociation is performed with trypsin and the NSC cell suspension is resuspended in growth medium. Dissociated stem cells can be plated on poly-L-lysine coated slides in DMEM + fetal bovine serum to encourage differentiation. Astrocyte differentiation can be stimulated by co-culturing with primary dissociated cultures of newborn CD-I mouse brain. Cells may be transfected so as to express a gene that promotes cell division, allowing cell proliferation in vitro without added growth factors. Processes for generating transfected cells are well known in the art.
  • the cells are transfected with an amphotrophic replication- incompetent retroviral vector, and the mitogenic gene is expressed from the viral LTR region.
  • the gene that promotes cell division does not encode a neural stimulant.
  • Preferred genes to be expressed are vmyc, SV-40 T antigen, ras oncogene, polyoma large T antigen, neu oncogene or combinations thereof.
  • proliferation-promoting genes and proteins are expressed or active in vitro but poorly expressed or inactive in vivo.
  • the vmyc gene appears to be self-regulating in this manner.
  • inducible promoters that require a factor, provided in vitro, to stimulate gene expression may be used.
  • Certain embryonal tumors contain many multipotent cell types.
  • cell lines established from these tumors may be used as part of a method for treating CNS injuries.
  • Useful cell lines derived from embryonal tumors have been described.
  • cells of the NT2/Tera cell line are capable of differentiating into all of the major neural lineages (U.S. Patent No. 5,175,103).
  • Such cells may be isolated from embryonal tumors by any of the general methods described above and in U.S. Patent No. 5,175,103 and in Andrews (1984) Dev. Biol. 103: 285- 293.
  • a human teratocarcinoma cell line (Ntera 2/C1.DI or NT2 cells) can be grown on retinoic acid to form a dense, multi-layered culture. These dense cultures are replated. Small, dense NT2-N cells are loosely associated with an underlying layer of cells. These can be easily dislodged and enriched, yielding a culture of small, round phase bright cells with some flat contaminating cells.
  • NT2-N cells can be further enriched by culturing with a combination of mitotic inhibitors, such as cytosine arabinoside.
  • mitotic inhibitors such as cytosine arabinoside.
  • the desired round cells are resistant to this treatment, while the flat cells do not proliferate.
  • Enrichment of NT2-N cells tending towards a neural developmental pathway stain with an anti-NF-L antibody (low molecular weight neurofilament protein), while undifferentiated NT2 cells (flat cells) stain with Cam5.2 which reacts with keratins 8 and 18.
  • Non-cancerous embryonic tissue is also a source for stem cells.
  • Early embryonic cells are totipotent, being capable of giving rise to the entire adult organism. As a result, such cells may be cultured to give totipotent or highly multipotent stem cells.
  • Embryonic stem cells may be used as part of an inventive method for treating CNS injuries. Depending on culture conditions, these cells may eventually give rise to more committed cell types and certain terminally differentiated cell types. Embryonic stem cells may be obtained and cultured as described in Thomson et al. (1998) Science 282:1145-1147; Evans et al. (1981) N ⁇ twre 292:154; Martin, G. (1981) Proc. Natl. Acad. Sci. USA 78:7634.
  • the molecule can be administered by any known route of administration, including intravenously, orally, or intracerebrally (e.g., intraventricularly, intrathecally, or intracisternally, or directly into the brain).
  • the dose may vary depending on the method of administration (see Table 2).
  • Doses determined in rats are typically scaled up for human treatments. The scaling to be used depends upon the method of delivery. If the stimulant is to be delivered systemically (eg. orally or intravenously) then the scaling is by body weight, where a typical rat weighs 300 grams and a typical human weighs 70 kg.
  • a typical rat brain has a surface area of 1 cm 2
  • a typical human brain has a surface area of 1000 - 10,000 cm 2 , depending upon whether all of the various folds buried in convolutions are counted or not.
  • scaling is done by brain mass.
  • a typical rat has a 2 g brain, while the typical human brain is 2 kg.
  • dosages can be adjusted according to the weight of the patient and other criteria. It is anticipated that effective dosage for all three general routes of administration may range from 0.001 - 1000 mg total for administration to spinal fluid or brain tissue. In preferred embodiments, the dosage may range from 0.01 - 100 mg, 0.1 - 10 mg or 0.5 - 5 mg.
  • intracisternal administration can consist of a single injection given, for example, six hours after an injury, a pair of injections, given, for example, 24 and 48 hours after an injury, or, if necessary, a series of injections of, for example, 0.1 mg/injection, or a 1 mg injection, given biweekly (for example, every 3-4 days) in a treatment regimen that occurs at least six hours following the ischemic episode.
  • the treatment regimen may last a number of weeks.
  • the cells are preferably administered directly into the stroke cavity, the spinal fluid, e.g., intraventricularly, intrathecally, or intracisternally.
  • the cells are carried in a pharmaceutically acceptable liquid medium, which can contain the bioactive molecule as well.
  • the cells can be administered to the stroke cavity or into the spinal fluid bathing the brain (e.g., intrathecal or intracisternal administration).
  • Cells may also be injected into the region of the brain surrounding the area(s) of damage, and cells may be given systemically, given the ability of certain stem cells to migrate to the appropriate position in the brain.
  • the cells are to be injected into the stroke cavity, the ventricles of the brain, or into the brain tissue, the patient's head is immobilized in a standard stereotactic frame, and the site of administration of the cells is located by standard CT or MRI scan. A small-bore hole is drilled in the skull, and the cells are injected into the desired location using a syringe.
  • Cells are scaled according to method of administration as detailed in table 2. Generally, between 10 6 and 10 12 cells are administered in total, preferably between 10 7 and 10 11 and more preferably between 10 8 and 10 10 . Multiple cell administrations can be used, generally at least 2-7 days apart.
  • Administration of cells and treatments will be preferably carried out anywhere from several hours or several days following the injury to several weeks or even months following the stroke. In preferred embodiments, administration is carried out at least 6, 10, 12 or 24 hours after the injury has occuned. It is anticipated that exact dosages for both cells and neural stimulants may be adjusted by the medical practitioner in response to the particular needs and characteristics of the patient. In general it is expected that the optimal dosage is high enough to be effective but low enough to avoid provoking excessive inflammatory response, which can be counter-productive. By determining the level of inflammatory response, one could determine whether a particular dosage rate is too high to give optimal effectiveness.
  • the methods of administration presented herein are preferred because they permit precise control and modulation of dose levels and because the area to which cells and stimulants are applied can be carefully controlled.
  • the neural stimulant is not produced from a transgene contained within one or more of the administered cells.
  • Other desirable compounds may be administered with the cells and neural stimulants.
  • immunosuppressants and antibiotics are useful for preventing graft rejection and infection, respectively.
  • these types of compounds may have additional beneficial effects.
  • Common methods of administering the cells and bioactive factors of the present invention to subjects, particularly human subjects, which are described in detail herein, include injection or implantation of the cells and/or neural stimulants into target sites in the subjects.
  • the cells and factors of the invention can be inserted into a delivery device which facilitates introduction by injection or implantation into the subjects.
  • delivery devices include tubes, e.g., catheters, for injecting cells and fluids into the body of a recipient subject.
  • the tubes additionally have a needle, e.g., a syringe, through which the cells of the invention can be introduced into the subject at a desired location.
  • the cells and factors of the invention can be inserted into such a delivery device, e.g., a syringe, in different forms.
  • the cells or factors can be suspended in a solution or embedded in a support matrix when contained in such a delivery device.
  • the term "solution” includes a pharmaceutically acceptable carrier or diluent in which the cells of the invention remain viable.
  • Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and/or dispersion media. The use of such carriers and diluents is well known in the art.
  • the solution is preferably sterile and fluid.
  • the solution is stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi through the use of, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • Solutions of the invention can be prepared by inco ⁇ orating progenitor cells as described herein in a pharmaceutically acceptable carrier or diluent and, as required, other ingredients enumerated above, followed by filtered sterilization.
  • cells may be administered on support matrices.
  • Support matrices in which cells can be inco ⁇ orated or embedded include matrices which are recipient-compatible and which degrade into products which are not harmful to the recipient.
  • Natural and/or synthetic biodegradable matrices are examples of such matrices.
  • Natural biodegradable matrices include plasma clots, e.g., derived from a mammal, and collagen matrices.
  • Synthetic biodegradable matrices include synthetic polymers such as polyanhydrides, polyorthoesters, and polylactic acid. Other examples of synthetic polymers and methods of inco ⁇ orating or embedding cells into these matrices are known in the art. See e.g., U.S. Patent No. 4,298,002 and U.S. Patent No. 5,308,701. These matrices provide support and protection for the cells in vivo.
  • Cells and neural stimulants of the invention may be administered together in a pharmaceutical composition.
  • Appropriate compositions may include all compositions usually employed for systemically or locally administering drugs.
  • the pharmaceutically acceptable carrier should be substantially inert, so as not to act with the active components or interfere with cell viability. Suitable inert carriers include water, alcohol polyethylene glycol, propylene glycol and the like.
  • compositions of this invention an effective amount of the particular neural stimulant and cells as active ingredients are combined with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration percutaneously, or by parenteral injection.
  • Any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility and cell viability, may be included.
  • Other ingredients may include antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives. If desired, further ingredients may be inco ⁇ orated in the compositions, e.g. anti- inflammatory agents, antibacterials, antifungals, disinfectants, vitamins, antibiotics.
  • antioxidants comprise butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, citric acid and ethoxyquin;
  • examples of chelating agents include disodium edetate and ethanehydroxy diphosphate;
  • examples of buffers comprise citric acid, sodium citrate, boric acid, borax, and disodium hydrogen phosphate;
  • examples of preservatives are methyl parahydroxybenzoate, ethyl parahydroxybenzoate, dehydroacetic acid, salicylic acid and benzoic acid.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • Examples of such dosage unit forms are capsules, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • compositions for use in the method of the present invention are those wherein the neural stimulant is formulated in liposome-containing compositions.
  • Liposomes are artificial vesicles formed by amphiphatic molecules such as polar lipids, for example, phosphatidyl cholines, ethanolamines and serines, sphingomyelins, cardiolipins, plasmalogens, phosphatidic acids and cerebiosides. Liposomes are formed when suitable amphiphathic molecules are allowed to swell in water or aqueous solutions to form liquid crystals usually of multilayer structure comprised of many bilayers separated from each other by aqueous material (also referred to as coarse liposomes).
  • Another type of liposome known to be consisting of a single bilayer encapsulating aqueous material is referred to as a unilamellar vesicle. If water-soluble materials are included in the aqueous phase during the swelling of the lipids they become entrapped in the aqueous layer between the lipid bilayers.
  • Water-soluble active ingredients are encapsulated in the aqueous spaces between the molecular layers.
  • a lipid soluble active ingredient of a neural stimulant such as an organic mimetic, is predominantly inco ⁇ orated into the lipid layers, although polar head groups may protrude from the layer into the aqueous space.
  • the encapsulation of these compounds can be achieved by a number of methods. The method most commonly used involves casting a thin film of phospholipid onto the walls of a flask by evaporation from an organic solvent. When this film is dispersed in a suitable aqueous medium, multilamellar liposomes are formed. Upon suitable sonication, the coarse liposomes form smaller similarly closed vesicles.
  • Water-soluble active ingredients are usually inco ⁇ orated by dispersing the cast film with an aqueous solution of the compound. The unencapsulated compound is then removed by centrifugation, chromatography, dialysis or other art-known suitable procedures. The lipid- soluble active ingredient is usually inco ⁇ orated by dissolving it in the organic solvent with the phospholipid prior to casting the film. If the solubility of the material in the lipid phase is not exceeded or the amount present is not in excess of that which can be bound to the lipid, liposomes prepared by the above method usually contain most of the material bound in the lipid bilayers; separation of the liposomes from unencapsulated material is not required.
  • a particularly convenient method for preparing liposome formulated forms of neural stimulants is the method described in EP-A-253,619, inco ⁇ orated herein by reference.
  • single bilayered liposomes containing encapsulated active ingredients are prepared by dissolving the lipid component in an organic medium, injecting the organic solution of the lipid component under pressure into an aqueous component while simultaneously mixing the organic and aqueous components with a high speed homogenizer or mixing means, whereupon the liposomes are formed spontaneously.
  • the single bilayered liposomes containing the encapsulated neural stimulant can be mixed with cells and then employed directly or they can be employed in a suitable pharmaceutically acceptable carrier for localized administration.
  • the viscosity of the liposomes can be increased by the addition of one or more suitable thickening agents such as, for example xanthan gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose and mixtures thereof.
  • suitable thickening agents such as, for example xanthan gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose and mixtures thereof.
  • the aqueous component may consist of water alone or it may contain electrolytes, buffered systems and other ingredients, such as, for example, preservatives.
  • Suitable electrolytes which can be employed include metal salts such as alkali metal and alkaline earth metal salts.
  • the preferred metal salts are calcium chloride, sodium chloride and potassium chloride.
  • the concentration of the electrolyte may vary from zero to 260 mM, preferably from 5 mM to 160 mM.
  • the aqueous component is placed in a suitable vessel which can be adapted to effect homogenization by effecting great turbulence during the injection of the organic component. Homogenization of the two components can be accomplished within the vessel, or, alternatively, the aqueous and organic components may be injected separately into a mixing means which is located outside the vessel. In the latter case, the liposomes are formed in the mixing means and then transferred to another vessel for collection pu ⁇ ose.
  • the organic component consists of a suitable non-toxic, pharmaceutically acceptable solvent such as, for example ethanol, glycerol, propylene glycol and polyethylene glycol, and a suitable phospholipid which is soluble in the solvent.
  • suitable phospholipids which can be employed include lecithin, phosphatidylcholine, phosphatydylserine, phosphatidylethanol- amine, phosphatidylinositol, lysophosphatidylcholine and phospha-tidyl glycerol, for example.
  • Other lipophilic additives may be employed in order to selectively modify the characteristics of the liposomes. Examples of such other additives include stearylamine, phosphatidic acid, tocopherol, cholesterol and lanolin extracts.
  • ingredients which can prevent oxidation of the phospholipids may be added to the organic component.
  • examples of such other ingredients include tocopherol, butylated hydroxyanisole, butylated hydroxytoluene, ascorbyl palmitate and ascorbyl oleate.
  • Preservatives such a benzoic acid, methyl paraben and propyl paraben may also be added.
  • Methods of introduction may also be provided by rechargeable or biodegradable devices.
  • Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals.
  • a variety of biocompatible polymers including hydrogels, including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a bioactive factor at a particular target site.
  • An essential feature of certain embodiments of the implant can be the linear release of the therapeutic, which can be achieved through the manipulation of the polymer composition and form.
  • the amount of water, porosity and consequent permeability characteristics can be controlled.
  • the selection of the shape, size, polymer, and method for implantation can be determined on an individual basis according to the disorder to be treated and the individual patient response.
  • the generation of such implants is generally known in the art. See, for example, Concise Encylopedia of Medical & Dental Materials, ed. by David Williams (MIT Press: Cambridge, MA, 1990); and the Sabel et al. U.S. Patent No. 4,883,666.
  • an implant cells are encapsulated in implantable hollow fibers or the like.
  • Such fibers can be pre-spun and subsequently loaded with the cell source (Aebischer et al. U.S. Patent No. 4,892,538; Aebischer et al. U.S. Patent No. 5,106,627; Hoffinan et al. (1990) Expt. Neurobiol. 110:39-44; Jaeger et al. (1990) Prog. Brain Res. 82:41-46; and Aebischer et al. (1991) J. Biomech. Eng.
  • Kits may include dose-size-specific ampules or aliquots of cells and/or neural stimulants. Kits may also contain devices to be used in administering the components of the conjoint administration. Such devices have been described above.
  • the kit may comprise a device for obtaining a cell sample from the patient from which stem cells will be cultured.
  • practitioners of the present invention may employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; Nucleic Acid Hybridization (B. D.
  • Example 1 Intracisternal neural stem cells (NSC) and growth factors enhance stoke recovery.
  • fetal mouse neural stem cells with or without basic fibroblast growth factor (bFGF) were administered intracisternally in a model of stroke recovery in rats.
  • NSC fetal mouse neural stem cells
  • bFGF basic fibroblast growth factor
  • animals were anesthetized by 2% halothane in a nitric oxide/oxygen mixture (2:1).
  • Focal cerebral infarction, (stroke) was performed by proximal electrocoagulation of the middle cerebral artery, as described previously (Kawamata et al. (1999) Exp. Neurol.
  • mice received an intracisternal injection of either: (1) vehicle, (2) NSC (10 6 cells), (3) bFGF (0.5 ⁇ g), or (4) NSC + bFGF.
  • Intracisternal injection in 50 ⁇ l total volume was done through percutaneous injection into the cisterna magna under halothane anesthesia. This same procedure was repeated two days later so that animals received treatment on days 1 and 3 following stroke.
  • Cyclosporin an immunosuppressant, was administered at 10 mg/kg, i.p. for the duration of the experiment.
  • a number of neurological tests were done to assess sensorimotor function of the contralateral limbs. These tests include both the forelimb and hindlimb placing tests which test the animal's ability to place the limb on a tabletop in response to visual, tactile, proprioceptive, and whisker stimulation.
  • a body swing test was done that measures the side to side preferences of the animal as he is held suspended by his tail above a tabletop.
  • the spontaneous limb use test is done which measures the animal's propensity to use each forelimb spontaneously as he rears up to explore the inside of a narrow glass cylinder.
  • the forelimb and hindlimb placing test, as well as the spontaneous limb use test reflect both cortical and striatal function.
  • the body swing test is mainly a measure of striatal function.
  • Panels (A) and (B) show placing activity of the affected forelimb and hindlimb (contralateral to the side of the stroke in the brain).
  • Panel (C) shows the body swing test, and panel (D) shows the spontaneous limb use test.
  • NSC nuclear-derived neurotrophic factor
  • Infarct volume was determined via image analysis, as described previously (Kawamata et al. (1996) J. Cereb. Blood Flow Metab. 16, 542-547; Kawamata et al. (1997) Proc. Nat. Acad. Sci. 94, 8179-8184). No significant differences were seen in infarct volume among groups, although there was a trend toward slightly smaller infarct volume in the groups receiving NSC.
  • the stem cells that were transplanted contain the lacZ reporter gene and express ⁇ -galactosidase. X-gal histochemistry was done to examine the location of these cells post-transplant. Indeed, the cells had migrated from their site of installation in the cisterna magna to positions surrounding the focal stroke in the right hemisphere.
  • this experiment showed that NSC and/or bFGF administered intracisternally starting one day after stroke can significantly enhance sensorimotor recovery of the contralateral limbs. This improvement was largely confined to tests reflecting cortical function. No significant differences were seen in infarct volume among the groups, suggesting that NSC and bFGF produced recovery-promoting effects through other mechanisms than the prevention of cell death. These mechanisms may include establishing new connections in undamaged parts of brain. Moreover in this first experiment, the combination of NSC and bFGF appeared to be slightly superior to either treatment alone.
  • Example 2 Direct intracerebral administration of NSC and intracisternal administration of bFGF enhance recovery in rat stroke model.
  • animals received either: (1) vehicle injection into periinfarct tissue, and vehicle injection into the cisterna magna, (2) NSC (10 6 cells) into periinfarct tissue and vehicle into the cisterna magna, (3) vehicle into periinfarct tissue and bFGF (0.5 ⁇ g) into the cisterna magna or (4) the combination NSC (10 6 cells) into periinfarct tissue and bFGF (0.5 ⁇ g) into the cisterna magna.
  • NSC was injected into striatal tissue at the margins of focal infarcts.
  • bFGF was injected percutaneously into the cisterna magna (intracisternal injection) as described previously (Kawamata et al. (1996) J. Cereb. Blood Flow Metab. 16, 542-547; Kawamata et al. (1997) Proc. Nat. Acad. Sci. 94, 8179-8184; Kawamata et al. (1999) Exp. Neurol. 158, 89-96). Rats also received cyclosporin, an immunosuppressant (10 mg/kg, i.p. per day), throughout the duration of the experiment.
  • NSC was injected directly into tissue bordering focal strokes.
  • bFGF was administered intracisternally.
  • Each of these treatments when delivered alone, improved behavioral outcome on some tests.
  • the combination treatment appeared to be better than either treatment alone. This was particularly apparent on the spontaneous limb use and paw reaching tests.
  • This experiment supports the notion that the combination of stem cell and growth factor treatment is superior to either treatment alone in enhancing stroke recovery. Both of the examples above were done using only one dose of NSC and growth factor. Further studies are underway to define the dose response characteristics of this interaction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés, des trousses et des compositions servant à favoriser le rétablissement d'un sujet suite à une lésion du système nerveux central. Dans certains aspects, les procédés de l'invention comportent l'administration de cellules et d'un neurostimulant à un sujet. Le rétablissement peut se manifester par des améliorations des capacités neuromotrices ou cognitives, p. ex. un contrôle et des mouvements améliorés des membres ou une capacité d'expression améliorée. Dans certaines formes de réalisation, les procédés mentionnés peuvent faire partie d'un traitement de lésions résultant d'une ischémie, d'une hypoxie ou d'un traumatisme.
EP00955755A 1999-08-18 2000-08-18 Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central Withdrawn EP1210106A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14956199P 1999-08-18 1999-08-18
US149561P 1999-08-18
PCT/US2000/022843 WO2001012236A2 (fr) 1999-08-18 2000-08-18 Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central

Publications (1)

Publication Number Publication Date
EP1210106A2 true EP1210106A2 (fr) 2002-06-05

Family

ID=22530841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00955755A Withdrawn EP1210106A2 (fr) 1999-08-18 2000-08-18 Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central

Country Status (10)

Country Link
EP (1) EP1210106A2 (fr)
JP (1) JP2003507349A (fr)
CN (1) CN1753686A (fr)
AU (1) AU6790300A (fr)
BR (1) BR0013388A (fr)
CA (1) CA2380953A1 (fr)
IL (1) IL148175A0 (fr)
MX (1) MXPA02001719A (fr)
NO (1) NO20020779L (fr)
WO (1) WO2001012236A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
AU2003216058A1 (en) * 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Mammalian neural stem cells, compositions and uses thereof
JP4583763B2 (ja) * 2002-04-08 2010-11-17 ザ スクリップス リサーチ インスティチュート 切断型２４ｋＤａ塩基性線維芽細胞成長因子
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7651459B2 (en) 2004-01-06 2010-01-26 Neuronetics, Inc. Method and apparatus for coil positioning for TMS studies
US8177702B2 (en) 2004-04-15 2012-05-15 Neuronetics, Inc. Method and apparatus for determining the proximity of a TMS coil to a subject's head
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US8088058B2 (en) 2005-01-20 2012-01-03 Neuronetics, Inc. Articulating arm
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
JP4943504B2 (ja) 2006-06-02 2012-05-30 ファイザー・プロダクツ・インク 循環腫瘍細胞アッセイ
DE102007003565B4 (de) 2007-01-24 2012-05-24 Forschungszentrum Jülich GmbH Vorrichtung zur Reduktion der Synchronisation neuronaler Hirnaktivität sowie dafür geeignete Spule
US9884200B2 (en) 2008-03-10 2018-02-06 Neuronetics, Inc. Apparatus for coil positioning for TMS studies
EP2326330B1 (fr) 2008-09-16 2015-01-07 University Of Central Florida Research Foundation, Inc. Compositions pour traiter et retarder le début de chute de cheveux
WO2012121971A2 (fr) 2011-03-04 2012-09-13 The Regents Of The University Of California Facteurs de croissance libérés localement pour favoriser la récupération motrice après un accident vasculaire cérébral
WO2013067770A1 (fr) * 2011-11-10 2013-05-16 Jinhui Chen Compositions et procédés pour le traitement d'une lésion cérébrale traumatique
CN103421800B (zh) * 2013-09-05 2015-07-22 新乡医学院 用于治疗脊髓损伤的重组基因、重组载体和重组细胞
CN103555747B (zh) * 2013-10-22 2015-04-08 深圳先进技术研究院 胶质细胞bFGF表达提高系统及其构建方法和应用
KR101897422B1 (ko) * 2014-08-15 2018-09-10 내셔날 헬스 리서치 인스티튜트 신경 줄기 세포 및 IL12p40을 활용하여 신경 재생을 증강하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
WO1994003199A1 (fr) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Procede ameliorant la differentiation et les chances de survie des cellules precurseurs neuronales
WO1995024469A1 (fr) * 1994-03-07 1995-09-14 Immunex Corporation Culture de cellules extra-corporelle et trousses de transplantation
AU734312B2 (en) * 1996-03-22 2001-06-07 General Hospital Corporation, The Administration of polypeptide growth factors following central nervous system ischemia or trauma
US20020136705A1 (en) * 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
PT1183035E (pt) * 1999-05-14 2015-03-04 Ford Henry Health System Transplante de medula óssea para tratamento de acidente vascular cerebral

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0112236A2 *

Also Published As

Publication number Publication date
NO20020779L (no) 2002-04-15
WO2001012236A2 (fr) 2001-02-22
CA2380953A1 (fr) 2001-02-22
JP2003507349A (ja) 2003-02-25
WO2001012236A3 (fr) 2001-08-30
WO2001012236A9 (fr) 2002-09-06
MXPA02001719A (es) 2003-09-25
AU6790300A (en) 2001-03-13
IL148175A0 (en) 2002-09-12
BR0013388A (pt) 2002-08-27
CN1753686A (zh) 2006-03-29
NO20020779D0 (no) 2002-02-15

Similar Documents

Publication Publication Date Title
WO2001012236A2 (fr) Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central
US20240226174A1 (en) Methods and compositions for provision of angiogenic factors
US6749850B1 (en) Methods, compositions and kits for promoting recovery from damage to the central nervous system
US9072740B2 (en) Methods of improving central nervous system functioning
US20050169896A1 (en) Bone marrow transplantation for treatment of stroke
JP2002530067A (ja) 細胞の低酸素培養
JP2006070040A (ja) 哺乳類の神経の増殖を促進する薬物
US20120076759A1 (en) Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
CN103237885B (zh) 用于细胞归巢和脂肪形成的组合物和方法
BRPI0620523A2 (pt) método de aumentar o potencial de implante e de atração celular, método de preparar células para transplante em um sujeito, população de células e composição farmacêutica
US20050054567A1 (en) Use of il-19,il-22 and il-24 to treat hematopoietic disorders
KR20010033834A (ko) 면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용
US20210246421A1 (en) Production method for neuron-like cells
EP0535148A4 (fr)
US20030104995A1 (en) Neuroprotective methods and compositions
KR101144687B1 (ko) Ｇ－ｃｓｆ 를 함유하는 선유아세포 동원제 및 창상 치료제
CN114765988A (zh) 吞噬的自组装蛋白
RU2803286C1 (ru) Композиция для нейропротекции и стимуляции нейрорегенерации головного мозга после повреждения, средство на ее основе, способ его получения и применения
US20190382728A1 (en) Menstrual Blood Derived Angiogenesis Stimulatory Cells
Al‐Kharboosh et al. Therapeutic potential and impact of nanoengineered patient‐derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma
WO2022224230A1 (fr) Traitement d'états médicaux par des greffes de cellules souches et activation de cellules souches
WO2023105526A1 (fr) Cellules progénitrices pulmonaires multipotentes pour la régénération pulmonaire
Li A study of hematopoietic and endothelial potentials of long-term cultured murine embryonic yolk sac cells and the establishment of an in vitro angiogenesis system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020318

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20021014

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHILDREN'S MEDICAL CENTER CORPORATION

Owner name: THE GENERAL HOSPITAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050405